Trader’s Watch List: Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR), Everest Re Group Ltd. (NYSE:RE), Limelight Networks, Inc. (NASDAQ:LLNW), DepoMed Inc. (NASDAQ:DEPO),

Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR), announced that the company will participate in the Cowen & Company 36th Annual Health Care Conference in Boston. Chief Executive Officer Mary Szela is scheduled to present on Wednesday, March 9, 2016 at 11:20 a.m. ET.

Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR) belongs to Healthcare sector. Its net profit margin is -18.50% and weekly performance is 0.17%. On last trading day company shares ended up at $5.77.

Everest Re Group, Ltd. (NYSE:RE) announced that its Board of Directors declared a dividend of $1.15 per share payable on or before March 23, 2016 to all shareholders of record as of March 9, 2016.

Everest Re Group Ltd. (NYSE:RE) shares increased 0.48% in last trading session and ended the day at $191.85. RE return on assets is 6.00%. Everest Re Group Ltd. (NYSE:RE) quarterly performance is 4.02%.

On 18 February, Limelight Networks, Inc. (NASDAQ:LLNW), announced that Akamai agreed in a hearing before the Massachusetts U.S. District Court to limit its maximum potential damages to $63 million plus future accruing interest (if any) in the longstanding patent dispute between the parties. This is a significant victory for Limelight, since Akamai previously requested $99 million. Limelight agreed to post a bond with the court to support the potential loss. The judge also set a briefing schedule, with a hearing set for mid-April, to determine the validity of the ‘703 patent due to intervening changes in the law of patentability and indefiniteness.

On 02 March, Limelight Networks, Inc. (NASDAQ:LLNW) shares increased 9.80% and was closed at $1.68. Limelight Networks, Inc. (NASDAQ:LLNW) year to date (YTD) performance is 15.07%.

On 29 February, Depomed (NASDAQ:DEPO) announced that top-line clinical results from a Phase IIb trial of GRT6005 (“cebranopadol’) conducted by Grünenthal GmbH (“Grünenthal”) in patients with moderate to severe chronic lower back pain (cLBP) have been posted to the European Clinical Trials Database (EudraCT). Results from the cLBP trial showed clinically and statistically significant improvements in pain at all three doses tested. In December, Depomed acquired the U.S. and Canadian rights to cebranopadol and its related follow-on compound from Grünenthal.

DepoMed Inc. (NASDAQ:DEPO) ended the last trading day at $15.12. Company weekly volatility is calculated as 5.63% and price to cash ratio as 4.36. DepoMed Inc. (NASDAQ:DEPO) showed a weekly performance of -11.63%.

SunEdison, Inc. (NYSE: SUNE) announced that it has suspended payment of quarterly dividends on the Company’s 6.75% Series A Perpetual Convertible Preferred Stock. Dividends on the Perpetual Convertible Preferred Stock are payable in cash or common stock (with a floor price of $7.34) and suspended dividends will accumulate in arrears. The Company’s Board of Directors intends to reassess its dividend policy on an ongoing basis.

SunEdison, Inc. (NYSE:SUNE) shares increased 19.33% in last trading session and ended the day at $1.79. SUNE Gross Margin is 17.60% and its return on assets is -7.30%. SunEdison, Inc. (NYSE:SUNE) quarterly performance is -43.89%.

Leave a Reply

Your email address will not be published. Required fields are marked *